bivalirudin,olpasiran
amgen
['bright-4', 'dose,trial']
#aha22 reviews bright-4, a randomised control trial designed to assess if bivalirudin plus a high dose infusion for 2-4 h post ppci was superior to unfractionated heparin in patients presenting w/ #stemi undergoing radial access ppci. 
PCR serves the needs of patients by helping the interventional cardiovascular community share knowledge experience practice. #EuroPCR @EuroInterventio